Efficient coexpression and secretion of anti-atherogenic human apolipoprotein Al and lecithin-cholesterol acytltransferase by cultured muscle cells using adeno-associated virus plasmid vectors

Gene Therapy

Volumn 5, Issue 10, 1998, Pages 1434-1440

  Fan, L ^a,b   Drew, J ^a   Dunckley, M G ^a   Owen, J S ^c   Dickson, G ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b NANJING MEDICAL UNIVERSITY   (China)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Adeno associated virus; Gene delivery; High density lipoproteins; Reverse cholesterol transport; Skeletal muscle

Indexed keywords

APOLIPOPROTEIN A1; COMPLEMENTARY DNA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLASMID VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DNA TRANSFECTION; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; MUSCLE FIBER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 0031727714     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300746     Document Type: Article

References (53)

1. Leroy A, Dallongeville J, Fruchart J. Apolipoprotein AI-containing lipoproteins and atherosclerosis. Curr Opin Lipidol 1995; 6: 281-285.
2. Forte TM, McCall MR. The role of apolipoprotein AI-containing lipoproteins in atherosclerosis. Cure Opin Lipidol 1994; 5: 354-364.
3. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport, J Lipid Res 1995; 36: 211-228.
4. Von Eckardstein A. Cholesterol efflux from macrophages and other cells. Curr Opin Lipidol 1996; 7: 308-319.
5. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996; 37: 2473-2491.
6. Rubin EM et al. Inhibition of early atherosclerosis in transgenic mice by human apolipoprotein AI. Nature 1991; 353: 265-267.
7. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density hpoprotein and suppress atherosclerosis in the apolipoprotein-E deficient mouse. Proc Natl Acad Sci USA 1994; 91: 9607-9611.
8. Liu AC Lawn RM, Verstuyft J, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein (a) in transgenic mice. J Lipid Res 1994; 35: 2263-2267.
9. Applebaum-Bowen D. Lipases and lecithin:cholesterol acyltransferase in the control of lipoprotein metabolism. Curr Opin Lipidol 1995; 6: 130-135.
10. Francone OL et al. Expression of human lecithin:cholesterol acyltransferase in transgenic mice: effects on cholesterol efflux, esterification and transport. J Lipid Res 1997; 38: 813-822.
11. Miyazaki A et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1882-1888.
12. Koizumi K et al. Behaviour of human apolipoprotein A-I:phospholipid and a poHDL:phospholipid complexes in vitro and after injection into rabbits. J Lipid Res 1988; 29: 1405-1415.
13. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994; 11: 517-521.
14. Thirry AR et al. Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA. Gene Therapy 1997; 4: 226-237.
15. Trivedi RA, Dickson G. Liposome-mediated dystrophin gene transfer. J Neurochem 1995; 64: 2230-2238.
16. Dodds E et al. Lipofection of cultured mouse muscle cells: a direct comparison of Lipofectamine and DOSPER. Gene Therapy 1997; 5: 542-552.
17. Yangihara I et al. Expression of full-length human dystrophin cDNA in mdx mouse muscle by HVJ-Iiposome injection. Gene Therapy 1996; 3: 549-553.
18. Wolff JA et al. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991; 11: 474-485.
19. Acsadi G et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991; 352: 815-818.
20. c diaphragm muscle fibres increases sarcolemmal stability. Gene Therapy 1997; 4: 401-408.
21. Baudard M et al. Expression of the human multidrug resistance and glucocerebrosidase cDNA from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum Gene Ther 1996; 7: 1309-1322.
22. Bartlett RJ et al. Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo. Cell Transplant 1996; 5: 411-419.
23. Dickson G. Gene transfer to muscle. Biochem Soc Trans 1996; 24: 513-519.
24. Bohl D, Naffakh N, Heard JM. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nature Med 1997; 3: 299-305.
25. Svensson EC, Tripathy SK, Leiden JM. Muscle-based gene therapy: realistic possibilities for the future. Molec Med Today 1996; 2: 166-172.
26. Chejanovsky N, Carter BJ. Mautagenesis of an AUG codon in the adeno-associated virus Rep gene: effects on viral DNA replication. Virology 1989; 173: 120-128.
27. Breslow JL et al. Isolation and characterisation of cDNA clones for human apolipoprotein A-I. Proc Natl Acad Sci USA 1982; 79: 6861-6865.
28. McLean J et al. Cloning and expression of human lecithin-cholesterol acyltransferase cDNA. Proc Natl Acad Sci USA 1982; 83: 2335-2339.
29. Driks W, Wirth M, Hauser H. Dicistronic transcription units for gene expression in mammalian cells. Gene 1993; 129: 247-249.
30. Chen C-H, Albers JJ. Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin:cholesterol acyltransferase activity. J Lipid Res 1982; 23: 680-691.
31. Gillett MPT, Owen JS. Cholesterol esterifying enzymes - lecithin:cholesterol acyltransferase (LCAT) and acylcoenzymeA:cholesterol acyltransferase (ACAT). In: Converse CA, Skinner RE (eds). Lipoprotein Analysis. IRL Press: Oxford, 1992, pp 187-201.
32. Flotte TR, Carter BJ. Adeno-associated virus vector for gene therapy. Gene Therapy 1995; 2: 357-362.
33. Lebkowsky JS, McNally MM, Okarma TB, Lerch LB. Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types Mol Cell Biol 1988; 8: 3988-3996.
34. Wei J-F, Wei F-S, Samulski RJ, Barranger JA. Expression of human glucocerebrosidase and arysulfatase A gene in murine and patient primary fibroblasts transduced by an adeno-associated virus vector. Gene Therapy 1994; 1: 261-268.
35. Kaplitt MG et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
36. Luo F et al. Adeno-associated virus 2-mediated gene transfer and functional expression of the human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1995; 23: 1261-1267.
37. Miller AD. Putting muscle to work for gene therapy. Nature Med 1997; 3: 278-279.
38. Philip R et al. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 1994; 14: 2411-2418.
39. Allan CM, Fidge NH, Kanellos J. Antibodies to the carboxyl terminal of human apolipoprotein A-I. The putative cellular binding domain of high density lipoprotein 3 and carboxyl terminal structural homology between apolipoprotein A-I and A-II. Biochem J 1994; 290: 449-455.
40. Xu S et al. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res 1997; 38: 1289-1298.
41. Minnich A et al. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein AI. Relation between lecithin-cholesterol acyltransferase activation and lipid binding. J Biol Chem 1992: 267: 16553-16560.
42. Sorci-Thomas M, Kearns MW, Lee JP. Apolipoprotein A-I domains involved in LCAT activation. Structural:function relationships. J Biol Chem 1993; 268: 21403-21409.
43. Schultz JR, Rubin EM. The properties of HDL in genetically engineered mice. Curr Opin Lipidol 1994; 5: 126-137.
44. Vaisman VL et al. Overexpression of human lecithin-cholesterol acyltransferase leads to hyperalphalipopoteinemia in transgenic mice. J Biol Chem 1995; 270: 12269-122275.
45. Duverger N et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation 1996; 94: 713-717.
46. Hoeg JM et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996; 93: 11448-11453.
47. Kopfler WP et al. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation 1994; 90: 1391-1327.
48. Seguret-Mace S et al. Potential gene therapy for LCAT-deficient and hyperalpha-lipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996; 941: 2177-2184.
49. Adam MA, Ramesh N, Miller AD, Osborne WRA. Internal initiation of translation in retrovirus vectors carrying picorna-virus 5′ nontranslated regions. J Virol 1991; 65: 4985-4990.
50. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989, pp 9.16-9.22.
51. Chawla D, Owen JS. Secretion of active lecithin-choiesterol acyltransferase by insect cells infected with a baculovirus. Biochem J 1995: 309: 249-253.
52. 6-tagged lecithin-cholesterol acyltransferase (LCAT) is catalytically active. Biochem Soc Trans 1998: 26: 5146.
53. Lima VLM et al. Characterization and use of rabbit polyclonal antibodies against human plasma lecithin-cholesterol acyltransferase. Braz J Med Biol Res 1996: 29: 957-968.